{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:03:21Z","timestamp":1784261001361,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Despite advances in new therapies, multiple myeloma (MM) remains incurable with most patients relapsing or becoming refractory to treatment demonstrating the need for novel therapeutic strategies. We previously identified VP79s, a novel guanidinium-based compound, with potent anti-myeloma activity which targets the dysregulated IL-6\/JAK\/STAT signalling pathway. Here, we aim to further evaluate the translational potential of VP79s by examining whether it synergises with the BH3 mimetic venetoclax and exploring the mechanisms underlying this effect. The pro-apoptotic effect of VP79s and venetoclax alone or in combination was assessed by annexin V\/propidium iodide staining followed by flow cytometry analysis. Western blotting was performed to evaluate the expression level of key pro- and anti-apoptotic members of the Bcl-2 family. BH3 profiling assessed apoptotic priming of cells to a Bim-domain peptide. Co-treatment of NCI-H929 and MM1.S cells with VP79s\/venetoclax resulted in a synergistic enhancement of apoptosis which correlated with a decrease in anti-apoptotic Mcl-1 and concurrent increase in pro-apoptotic Bim S. Synergy was not observed in U266B1 cells possibly because these cells demonstrated relative resistance to venetoclax and exhibited a lower level of apoptotic priming in response to a Bim peptide. Importantly, co-treatment of NCI-H929 cells with VP79s and venetoclax was shown to overcome bone marrow stromal cell induced drug resistance. Preliminary findings also indicate that the combination treatment induced an enhanced reduction in viability of ex vivo myeloma patient samples with minimal cytotoxicity toward healthy donor lymphocytes observed. These findings support further preclinical investigation of VP79s in combination with venetoclax as a potential therapeutic strategy in MM.<\/jats:p>","DOI":"10.1007\/s10637-026-01629-9","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:06:49Z","timestamp":1784257609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells"],"prefix":"10.1007","author":[{"given":"Yunlong","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Previtali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Minneci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"McElligott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Zisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"5","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"1629_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, Manier S, Mohty M (2024) Multiple myeloma. Nat Rev Dis Primers 10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7","journal-title":"Nat Rev Dis Primers"},{"key":"1629_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103193","author":"K Sun","year":"2025","unstructured":"Sun K, Wu H, Zhu Q, Gu K, Wei H, Wang S, Li L, Wu C, Chen R, Pang Y, Han B, Zeng H, Liu M, Zheng R, Wei W (2025) Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: population-based estimates from GLOBOCAN 2022. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103193","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1629_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0284-7","volume":"10","author":"CR Marinac","year":"2020","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR (2020) Dissecting racial disparities in multiple myeloma. Blood Cancer J 10(2):19. https:\/\/doi.org\/10.1038\/s41408-020-0284-7","journal-title":"Blood Cancer J"},{"issue":"1","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, Anderson KC, Ghobrial IM (2015) Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 263(1):160\u2013172. https:\/\/doi.org\/10.1111\/imr.12233","journal-title":"Immunol Rev"},{"issue":"3","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","volume":"33","author":"K Brigle","year":"2017","unstructured":"Brigle K, Rogers B (2017) Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs 33(3):225\u2013236. https:\/\/doi.org\/10.1016\/j.soncn.2017.05.012","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2021","unstructured":"Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang J-M, Yang-Yen H-F, Karras J, Jove R Jr, T P L (2021) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107(3):351\u2013362. https:\/\/doi.org\/10.1172\/JCI9940","journal-title":"J Clin Invest"},{"issue":"1","key":"1629_CR9","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2020-0001","volume":"7","author":"JJH Tang","year":"2020","unstructured":"Tang JJH, Thng DKH, Lim JJ, Toh TB (2020) JAK\/STAT signaling in hepatocellular carcinoma. Hepat Oncol 7(1):HEP18. https:\/\/doi.org\/10.2217\/hep-2020-0001","journal-title":"Hepat Oncol"},{"issue":"4","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1073\/pnas.1211805110","volume":"110","author":"OA Timofeeva","year":"2013","unstructured":"Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, Brown ML, Dritschilo A (2013) STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A 110(4):1267\u20131272. https:\/\/doi.org\/10.1073\/pnas.1211805110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12541","volume":"277","author":"B Tummers","year":"2017","unstructured":"Tummers B, Green DR (2017) Caspase-8: regulating life and death. Immunol Rev 277(1):76\u201389. https:\/\/doi.org\/10.1111\/imr.12541","journal-title":"Immunol Rev"},{"issue":"5","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41580-022-00564-w","volume":"24","author":"P Vandenabeele","year":"2023","unstructured":"Vandenabeele P, Bultynck G, Savvides SN (2023) Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nat Rev Mol Cell Biol 24(5):312\u2013333. https:\/\/doi.org\/10.1038\/s41580-022-00564-w","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner C-M, Roberts AW, Jurczak W, Mulligan SP, B\u00f6ttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek H, Wierda WG (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768\u2013778. https:\/\/doi.org\/10.1016\/S1470-2045(16)30019-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"1629_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01434-2","volume":"16","author":"MS Davids","year":"2026","unstructured":"Davids MS, Stilgenbauer S, Tam CS (2026) First-line treatment for CLL in the era of targeted therapy. Blood Cancer J 16(1):19. https:\/\/doi.org\/10.1038\/s41408-025-01434-2","journal-title":"Blood Cancer J"},{"key":"1629_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03542-2","author":"Y Xu","year":"2026","unstructured":"Xu Y, Nguyen J, Miu K, Lin C-W, Montez M, Chai X, Chen X, LeBlanc TW (2026) Budget impact of venetoclax for newly diagnosed patients with acute myeloid leukemia aged \u2265 75 years or with comorbidities precluding intensive chemotherapy in the United States. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-026-03542-2","journal-title":"Adv Ther"},{"issue":"1","key":"1629_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Neto JVP, Campos LT, Hamerschlak N (2018) BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol 11(1):65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2","journal-title":"J Hematol Oncol"},{"key":"1629_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1501950","author":"M Markouli","year":"2025","unstructured":"Markouli M, Pagoni MN, Diamantopoulos P (2025) BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1501950","journal-title":"Front Oncol"},{"issue":"3","key":"1629_CR18","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","volume":"102","author":"C Touzeau","year":"2017","unstructured":"Touzeau C, Gouill SL, Mah\u00e9 B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P (2017) Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica 102(3):e112\u2013e114. https:\/\/doi.org\/10.3324\/haematol.2016.160408","journal-title":"Haematologica"},{"issue":"5","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, Boise LH (2016) Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30(5):1086\u20131093. https:\/\/doi.org\/10.1038\/leu.2015.350","journal-title":"Leukemia"},{"key":"1629_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120236","author":"R Amet","year":"2022","unstructured":"Amet R, Previtali V, Mihigo HB, Sheridan E, Brophy S, Hante NK, Santos-Martinez MJ, Hayden PJ, Browne PV, Rozas I, McElligott AM, Zisterer DM (2022) A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2021.120236","journal-title":"Life Sci"},{"issue":"3","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.3324\/haematol.2018.212308","volume":"105","author":"EM Algar\u00edn","year":"2020","unstructured":"Algar\u00edn EM, D\u00edaz-Tejedor A, Mogoll\u00f3n P, Hern\u00e1ndez-Garc\u00eda S, Corchete LA, San-Segundo L, Mart\u00edn-S\u00e1nchez M, Gonz\u00e1lez-M\u00e9ndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Guti\u00e9rrez NC, Mateos M-V, Pa\u00edno T, Garayoa M, Ocio EM (2020) Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica 105(3):e116\u2013e120. https:\/\/doi.org\/10.3324\/haematol.2018.212308","journal-title":"Haematologica"},{"issue":"20","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2022017341","volume":"140","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D (2022) Mechanisms of resistance to venetoclax. Blood 140(20):2094\u20132096. https:\/\/doi.org\/10.1182\/blood.2022017341","journal-title":"Blood"},{"issue":"1","key":"1629_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-025-04989-8","volume":"12","author":"VK Hughitt","year":"2025","unstructured":"Hughitt VK, Simmons JK, Gorjifard S, Michalowski A, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Michael S, Keats J, Thomas C, Mock BA (2025) Large-scale human myeloma cell line small molecule compound screen dataset. Sci Data 12(1):661. https:\/\/doi.org\/10.1038\/s41597-025-04989-8","journal-title":"Sci Data"},{"issue":"12","key":"1629_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph13120485","volume":"13","author":"V Previtali","year":"2020","unstructured":"Previtali V, Mihigo HB, Amet R, McElligott AM, Zisterer DM, Rozas I (2020) Exploring the anti-cancer mechanism of novel 3,4\u2032-substituted diaryl guanidinium derivatives. Pharmaceuticals (Basel) 13(12):485. https:\/\/doi.org\/10.3390\/ph13120485","journal-title":"Pharmaceuticals (Basel)"},{"key":"1629_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-0716-3056-3_10","volume":"2645","author":"S Brophy","year":"2023","unstructured":"Brophy S, Amet R, Foy-Stones H, Gardiner N, McElligott AM (2023) Isolation and Cryopreservation of MononuclearCells from Peripheral Blood and Bone Marrow of Blood Cancer Patients. Methods Mol Biol 2645:179\u2013187. https:\/\/doi.org\/10.1007\/978-1-0716-3056-3_10","journal-title":"Methods Mol Biol"},{"issue":"9","key":"1629_CR26","doi-asserted-by":"publisher","first-page":"12347","DOI":"10.3390\/s120912347","volume":"12","author":"SN Rampersad","year":"2012","unstructured":"Rampersad SN (2012) Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 12(9):12347\u201312360. https:\/\/doi.org\/10.3390\/s120912347","journal-title":"Sensors (Basel)"},{"key":"1629_CR27","doi-asserted-by":"publisher","unstructured":"Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 10355\u201398. https:\/\/doi.org\/10.1016\/B978-0-12-385493-3.00004-8","DOI":"10.1016\/B978-0-12-385493-3.00004-8"},{"issue":"1","key":"1629_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.113995","volume":"437","author":"T Gao","year":"2024","unstructured":"Gao T, Magnano S, Rynne A, O\u2019Kane L, Barroeta PH, Zisterer DM (2024) Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin. Exp Cell Res 437(1):113995. https:\/\/doi.org\/10.1016\/j.yexcr.2024.113995","journal-title":"Exp Cell Res"},{"key":"1629_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2025.106250","volume":"174","author":"T Gao","year":"2025","unstructured":"Gao T, Magnano S, Quadros M, Barroeta PH, Zisterer DM (2025) The pan-BH-3 mimetic, obatoclax, synergistically enhances cisplatin-induced apoptosis in oral squamous cell carcinoma through a mechanism that involves degradation of the pro-survival protein Mcl-1. Arch Oral Biol 174:106250. https:\/\/doi.org\/10.1016\/j.archoralbio.2025.106250","journal-title":"Arch Oral Biol"},{"key":"1629_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep40752","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang L, Jiang Y, Chen Y (2017) Predicting drug combination index and simulating the network-regulation dynamics by mathematical modeling of drug-targeted EGFR-ERK signaling pathway. Sci Rep 7:40752. https:\/\/doi.org\/10.1038\/srep40752","journal-title":"Sci Rep"},{"issue":"9","key":"1629_CR31","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","volume":"52","author":"M Hao","year":"2011","unstructured":"Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H, Qiu L (2011) Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 52(9):1787\u20131794. https:\/\/doi.org\/10.3109\/10428194.2011.576791","journal-title":"Leuk Lymphoma"},{"key":"1629_CR32","doi-asserted-by":"publisher","unstructured":"Liu Q, Osterlund EJ, Chi X, Pogmore J, Leber B, Andrews DW (2019) Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. Elife 8\u306e7689. https:\/\/doi.org\/10.7554\/eLife.37689","DOI":"10.7554\/eLife.37689"},{"key":"1629_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88329","volume":"12","author":"JM Pemberton","year":"2023","unstructured":"Pemberton JM, Nguyen D, Osterlund EJ, Schormann W, Pogmore JP, Hirmiz N, Leber B, Andrews DW (2023) The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes. Elife 12:e88329. https:\/\/doi.org\/10.7554\/eLife.88329","journal-title":"Elife"},{"issue":"4","key":"1629_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200610148","volume":"177","author":"A Weber","year":"2007","unstructured":"Weber A, Paschen SA, Heger K, Wilfling F, Frankenberg T, Bauerschmitt H, Seiffert BM, Kirschnek S, Wagner H, H\u00e4cker G (2007) BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 177(4):625\u2013636. https:\/\/doi.org\/10.1083\/jcb.200610148","journal-title":"J Cell Biol"},{"issue":"11","key":"1629_CR35","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1128\/MCB.22.11.3577-3589.2002","volume":"22","author":"M Marani","year":"2002","unstructured":"Marani M, Tenev T, Hancock D, Downward J, Lemoine NR (2002) Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol 22(11):3577\u20133589. https:\/\/doi.org\/10.1128\/MCB.22.11.3577-3589.2002","journal-title":"Mol Cell Biol"},{"issue":"6009","key":"1629_CR36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.1190217","volume":"330","author":"D Ren","year":"2010","unstructured":"Ren D, Tu H-C, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ-D, Cheng EH-Y (2010) BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330(6009):1390\u20131393. https:\/\/doi.org\/10.1126\/science.1190217","journal-title":"Science"},{"issue":"5","key":"1629_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1947601911417177","volume":"2","author":"R Elkholi","year":"2011","unstructured":"Elkholi R, Floros KV, Chipuk JE (2011) The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer 2(5):523\u2013537. https:\/\/doi.org\/10.1177\/1947601911417177","journal-title":"Genes Cancer"},{"issue":"7","key":"1629_CR38","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ (2022) Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res 12(7):2950\u20132965","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1629_CR39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/jphp.13240","volume":"72","author":"KY Wong","year":"2020","unstructured":"Wong KY, Chim CS (2020) Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol 72(5):728\u2013737. https:\/\/doi.org\/10.1111\/jphp.13240","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"1629_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2505-1","volume":"11","author":"C Seiller","year":"2020","unstructured":"Seiller C, Maiga S, Touzeau C, Bellanger C, Kervo\u00eblen C, Descamps G, Maillet L, Moreau P, Pellat-Deceunynck C, Gomez-Bougie P, Amiot M (2020) Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes. Cell Death Dis 11(5):316. https:\/\/doi.org\/10.1038\/s41419-020-2505-1","journal-title":"Cell Death Dis"},{"issue":"12","key":"1629_CR41","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1080\/10428194.2023.2244102","volume":"64","author":"EC Dominguez","year":"2023","unstructured":"Dominguez EC, Roleder C, Ball B, Danilov AV (2023) Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications. Leuk Lymphoma 64(12):1893\u20131904. https:\/\/doi.org\/10.1080\/10428194.2023.2244102","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1629_CR42","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie P, Wuill\u00e8me-Toumi S, M\u00e9noret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67(11):5418\u20135424. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4322","journal-title":"Cancer Res"},{"issue":"1","key":"1629_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01306-7","volume":"14","author":"L Cao","year":"2022","unstructured":"Cao L, Chen Q, Gu H, Li Y, Cao W, Liu Y, Qu J, Hou Y, Chen J, Zhang E, He J, Cai Z (2022) Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression. Clin Epigenetics 14(1):83. https:\/\/doi.org\/10.1186\/s13148-022-01306-7","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1629_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01215-x","volume":"15","author":"R Fonseca","year":"2025","unstructured":"Fonseca R, Zhu YX, Bruins LA, Ahmann J, Campos CdB, Braggio E, Chen X, Arribas M, Darvish S, Welsh S, Meermeier E, Mangalaparthi KK, Kandasamy RK, Ahmann G, Wiedmeier-Nutor JE, Pandey A, Chesi M, Bergsagel PL, Fonseca R (2025) Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention. Blood Cancer J 15(1):10. https:\/\/doi.org\/10.1038\/s41408-025-01215-x","journal-title":"Blood Cancer J"},{"issue":"4","key":"1629_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01636-1","volume":"39","author":"J Borowczak","year":"2022","unstructured":"Borowczak J, Szczerbowski K, Ahmadi N, Szylberg \u0141 (2022) CDK9 inhibitors in multiple myeloma: a review of progress and perspectives. Med Oncol 39(4):39. https:\/\/doi.org\/10.1007\/s12032-021-01636-1","journal-title":"Med Oncol"},{"issue":"26","key":"1629_CR46","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, Oberlton B, Joseph NS, Hofmeister CC, Heffner LT, Dhodapkar MV, Nooka AK, Lonial S, Mitsiades CS, Kaufman JL, Boise LH (2021) Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood 137(26):3604\u20133615. https:\/\/doi.org\/10.1182\/blood.2020007899","journal-title":"Blood"},{"issue":"5","key":"1629_CR47","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH (2011) Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 118(5):1329\u20131339. https:\/\/doi.org\/10.1182\/blood-2011-01-327197","journal-title":"Blood"},{"issue":"1","key":"1629_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15051-z","volume":"11","author":"R Bajpai","year":"2020","unstructured":"Bajpai R, Sharma A, Achreja A, Edgar LC, Wei C, Siddiqa AA, Gupta VA, Matulis SM, McBrayer SK, Mittal A, Rupji M, Barwick BG, Lonial S, Nooka AK, Boise LH, Nagrath D, Shanmugam M (2020) Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun 11(1):1288. https:\/\/doi.org\/10.1038\/s41467-020-15051-z","journal-title":"Nat Commun"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01629-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:06:52Z","timestamp":1784257612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01629-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":48,"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01629-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the St James\u2019s Hospital and Tallaght Hospital Joint Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}